Tags : AVEO Oncology

AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3

Shots: The P-III TIVO-3 study involves assessing of Fotivda (tivozanib) vs sorafenib in 350 patients with refractory advanced or metastatic renal cell carcinoma (RCC) P-III TIVO-3 results: 44% improvement in mPFS; 26% reduction in the risk of progression or death; mPFS (5.6 vs 3.9 mos.); ORR (18% vs 8%), presented at ASCO Genitourinary Cancers Symposium, […]Read More

AstraZeneca and AVEO Oncology Enter into an Immuno-Oncology Clinical Collaboration

Shots: AstraZeneca and AVEO collaborates to evaluate safety and efficacy of AstraZeneca’s Imfinzi (durvalumab) + AVEO’s Fotivda (tivozanib) in P-I/II for 1L HCC or liver cancer AVEO plans to initiate the onset of P-I trial for the combination therapy in 2019, with equal cost sharing Imfinzi (durvalumab) is mAb binds with PD-L1, further blocking its interaction with PD-1 and […]Read More